Associated Papers
High Frequency of CTNNB1 Variants Associated with Benign and Malignant Liver Tumors in Patients with Congenital Porto-Systemic Shunts.
Tyraskis A et al.
Liver Cancer, 2025
40831883 (PubMed )
Supplement: Supplementary_material-Suppl.1-s1.docx
Correlation between CTNNB1 mutation status and tumour phenotype in hepatitis B virus-related hepatocellular carcinoma.
Hwang YJ et al.
Histopathology, 2025
A systematic analysis with the hierarchical cluster analysis strategy on the complex interaction of TERT and CTNNB1 somatic mutations in Vietnamese hepatocellular carcinoma patients.
Thu Nguyen T et al.
Gene, 2024
Pharmacogenomic profiling of intra-tumor heterogeneity using a large organoid biobank of liver cancer.
Yang H et al.
Cancer Cell, 2024
CTNNB1 mutations, TERT polymorphism and CD8+ cell densities in resected hepatocellular carcinoma are associated with longer time to recurrence.
Ambrozkiewicz F et al.
Bmc Cancer, 2022
35962322 (PubMed )
Supplement: 12885_2022_9989_MOESM1_ESM.xlsx › Supplementary_table_1
Somatic reversion impacts myelodysplastic syndromes and acute myeloid leukemia evolution in the short telomere disorders.
Schratz KE et al.
The Journal of Clinical Investigation, 2021
Molecular Scoring of Hepatocellular Carcinoma for Predicting Metastatic Recurrence and Requirements of Systemic Chemotherapy.
Nishida N et al.
Cancers, 2018
30274313 (PubMed )
Supplement: cancers-10-00367-s001.zip › Supplementary_Table_S5.xlsx › Supplementary_Table_7.xls
Select a paper to view details